Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Buys 61,523 Shares of Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the acquisition, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. acquired 6,146 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.89 per share, with a total value of $152,973.94.
• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. bought 3,802 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. bought 6,387 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Trading Up 3.7%

Shares of COAG opened at $26.45 on Thursday. Hemab Therapeutics Holdings, Inc. has a twelve month low of $23.00 and a twelve month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on COAG shares. Wedbush initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target for the company. Jefferies Financial Group initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Evercore began coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $41.40.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.